Global Hepatitis C Virus (HCV) Market Report: 2016 Edition

  • ID: 3639913
  • Report
  • Region: Global
  • 60 Pages
  • Koncept Analytics
1 of 6
Development of new therapies likely to affect the HCV Market

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Johnson & Johnson
  • MORE
Hepatitis C Virus (HCV) is an infection which affects the liver which may lead to serious consequences if not taken care of. It spreads through infected blood transfusions and poorly sterilized medical equipments. The number of patients has increased significantly because its symptoms take time to be recognized before the patient progresses towards a clinically visible liver damage which worsens the situation since it may lead to liver damage or even failure. There was no proper therapy for HCV before 2010 but the coming of therapies like Sovaldi and Harvoni by Gilead and Viekira Pak by AbbVie has improved the scenario. Also the steps taken like proper blood screening is also helping in identifying the patients.

The key factors which are anticipated to drive HCV market include medical reimbursement because of the therapy being very costly, growth in the number of patients, relatively smaller period of drug treatment from before, treatment of the warehoused patients who were waiting for a better therapy and pricing discounts and better regimens because of the increased competition. Some of the significant developments of this industry include launch of the interferon free regimen and development of products like Sovaldi, Harvoni and Viekira Pak and the newly identified and diagnosed patients. However, the challenges to be faced ahead is more number of patients asking for reimbursement, increasing competition leading to price cutting, risk associated with drug development and regulatory risk.

This report offers a comprehensive analysis of the HCV market. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global HCV market is reined by few major players namely Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the market. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Johnson & Johnson
  • MORE
1. HCV Market

1.1 An Introduction
1.2 Types of Hepatitis C Virus
1.3 Ways of Spreading of HCV Infection
1.4 HCV Co Infections
1.5 Avoidance of HCV Infection

2. Global HCV Market

2.1 Global HCV Sales by Value
2.2 Global HCV Prevalence by Region

3. Global HCV Market by Region

3.1 The US Market
3.1.1 The US HCV Sales by Value
3.1.2 The US HCV Market Dynamics
3.1.3 HCV Patients Initiated Treatment with Sofosbuvir
3.2 European Union HCV Sales by Value
3.3 Japan HCV Sales by Value
3.4 ROW HCV Sales by Value

4. Market Dynamics

4.1 Growth Drivers

4.1.1 Impact of Reimbursement
4.1.2 Growth in Number of Patients
4.1.3 Smaller Period of Drug Treatment
4.1.4 Improved Economic Growth
4.1.5 Increasing Healthcare Expenditure
4.1.6 Treatment of Warehoused Patients
4.1.7 Global Ageing Population
4.1.8 Pricing Discounts and Better Regimen

4.2 Trends and Development

4.2.1 Launch of Interferon Free Regimen and Development of New Products
4.2.1 Newly Identified and Diagnosed Patients

4.3 Challenges

4.3.1 Increase in Number of Patients for Reimbursement
4.3.2 Increased Competition leading to Price Cut
4.3.3 Risk Associated with Drug Development and Patent
4.3.4 Regulatory Risk

5. Competitive Landscape

5.1 Global Market
5.2 Global Product Sales
5.3 Viekira Vs. Harvoni - Current US Market Scenario
5.4 Viekira Vs. Harvoni - Future US Market Scenario

6. Company Profiles

6.1 Gilead Sciences

6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies

6.2 AbbVie

6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies

6.3 Johnson & Johnson

6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies

6.4 Bristol-Myers Squibb

6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

7. Market Outlook

7.1 Market Forecast
7.2 Forecast Methodology
7.2.1 Dependent and Independent Variables
7.2.2 Correlation Analysis
7.2.3 Regression Analysis

List of Charts

- Types of Hepatitis C Virus (HCV)
- Natural History of HCV Infection
- Global HCV Market by Value (2011-2015)
- HCV Genotype 1 Patients in Emerging Markets (2015)
- Global Deaths Due to HCV (2010-2014)
- The US HCV Market by Value (2011-2015)
- The US HCV Market Dynamics (2014)
- Total Estimated HCV Patients to be treated in US (2015)
- Total Estimated Genotype1 Patients to be treated in the US (2015)
- Estimated HCV Patients to be treated in the US (2016E-2029E)
- Patients Initiating Treated with Sofosbuvir Based Regimen (2015)
- HCV Patients Initiated Treatment with Sofosbuvir based Regimen by Genotype (2015)
- HCV Patients Initiated Treatment with Sofosbuvir based Regimen by Fibrosis Score (2015)
- HCV Patients Initiated Treatment with Sofosbuvir based Regimen by Patient Type (2015)
- EU HCV Market by Value (2011-2015)
- Estimated Number of Patients to be treated in EU (2016E - 2029E)
- Japanese HCV Market by Value (2011-2015)
- Estimated Number of Patients to be treated in Japan (2016E-2029E)
- Rest of World HCV Market by Value (2011-2015)
- Reimbursement Situation (2015)
- Global GDP Growth (2006-2014)
- Global Healthcare Expenditure (2007-2014)
- Frequency of Patients Warehoused Currently by Doctors (2014)
- Warehoused Patients Expected to be treated in 2015
- Warehoused Patients Expected to be treated in 2016
- Global Ageing Population (2006-2014)
- Mix of Doctors in Survey (2014)
- Frequency of New Patients Treated per Month (2014)
- Newly Identified Patients per Year (2015E-2029E)
- Percentage of New Diagnosed Patients (2015E - 2029E)
- Global Market Share of HCV and HBV (2014)
- Global Market Share of HCV and HBV (2020E)
- Global Sales of Sovaldi, Harvoni and Viekira Pak (2015)
- The US Market Share of Viekira and Harvoni (2014)
- Factors Affecting the Growth of Viekira (2014)
- Factors affecting while Prescription of Harvoni and Viekira (2014)
- The US Market Share by Company (2016E)
- Gilead Revenue and Net Income (2010-2014)
- AbbVie Revenue and Net Income (2010-2014)
- J&J’s Consumer Sales by Segment (2014)
- J&J’s Pharmaceutical Sales by Segment (2014)
- Global Medical Devices Sales by Segment (2014)
- Johnson & Johnson Revenue and Net Income (2010-2014)
- J&J’s Research & Development Expenses by Segment (2013-2014)
- Bristol Myers Squibb Revenue and Net Income (2010-2014)
- Bristol-Myers Revenue by Region (2014)
- Global HCV Market Forecast (2014-2019E)

List of Tables

- Different Ways of Transmission of HCV
- Global HCV Prevalence by Region (2014)
- Summary of Survey Population
- Market Share Based on Contracted Lives
- Clinical Factors Affecting Market Share of AbbVie Vs. Gilead (2014)
- Cure Rates with New Direct Acting anti-Viral - DAA (2014)
- Viekira Pak Pill Order
- Future Regimens of Gilead, AbbVie and Merck
- Dependent & Independent Variables (2011-2015)
- Correlation Matrix
- Model Summary - Coefficient of Determination
- Regression Coefficients Output
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Johnson & Johnson
  • MORE
The hepatitis C virus (HCV) primarily affects the liver. The treatment for HCV has improved now because of the launch of new therapies like Sovaldi, Harvoni and Viekira Pak with improved efficiency, tolerability and shorter duration of treatment. Many new therapies are under clinical trials for achieving more efficiency and cure rate. HCV mainly spreads through blood transfusion and poorly sterilized medical equipments resulting in liver cirrhosis and even leading to liver failure

The main reason that many patients go undiagnosed and not aware of the infection is because it affects very slowly and its symptoms take years to be recognized but today initiatives like proper blood screening has helped in recognizing more patients. Regular alcohol consumption and taking of drugs are also the reasons for getting caught by the infection. Manu people use to skip the therapy till some years back because of long duration of treatment and being very costly but the market is increasing due to the coming of more effective therapies and reimbursement policies.

As per the report "HCV Market: 2016 Edition", the demand for HCV will be driven by comfort of reimbursement, growth in the number of patients, smaller period of drug treatment, increasing healthcare expenditure and treatment of warehoused patients. Some of the noteworthy trends and developments of this industry are launch of interferon free regimen and development of new products. However, the expansion of HCV market is hindered by regulatory risks, patent risk, risk associated with drug development and increased competition.

The report presents an in-depth analysis of the global market along with a focus on all major regions. A thorough analysis has been conducted on key market players covering their business overview, product portfolio, financial overview and business strategies.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Note: Product cover images may vary from those shown
5 of 6
- AbbVie
- Bristol-Myers Squibb
- Gilead Sciences
- Johnson & Johnson
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll